The growing role of precision and personalized medicine for cancer treatment

Abstract

Cancer is a devastating disease that takes the lives of hundreds of thousands of people every year. Due to disease heterogeneity, standard treatments, such as chemotherapy or radiation, are effective in only a subset of the patient population. Tumors can have different underlying genetic causes and may express different proteins in one patient versus another. This inherent variability of cancer lends itself to the growing field of precision and personalized medicine (PPM). There are many ongoing efforts to acquire PPM data in order to characterize molecular differences between tumors. Some PPM products are already available to link these differences to an effective drug. It is clear that PPM cancer treatments can result in immense patient benefits, and companies and regulatory agencies have begun to recognize this. However, broader changes to the healthcare and insurance systems must be addressed if PPM is to become part of standard cancer care.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 195

1. 1.

   National Cancer Institute. Cancer statistics (2018 ), https://www.cancer.gov/about-cancer/understanding/statistics

   Not in our library

2. 2.

   National Cancer Institute. Cancer types (2018 ), https://www.cancer.gov/types

   Not in our library

3. 3.

   Alizadeh AA Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000 ).

   Not in our library10.1038/35000501

4. 4.

   Guinney J The consensus molecular subtypes of colorectal cancer. Nat. Med 21, 1350–1356 (2015 ).

   Not in our library10.1038/nm.3967

5. 5.

   Perou CM Molecular portraits of human breast tumours. Nature 406, 747–752 (2000 ).

   Not in our library10.1038/35021093

6. 6.

   Davies H Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002 ).

   Not in our library10.1038/nature00766

7. 7.

   National Cancer Institute. Types of cancer treatment (2017 ), https://www.cancer.gov/about-cancer/treatment/types

   Not in our library

8. 8.

   Morgan G, Ward R & Barton M The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin. Oncol. (R. Coll. Radiol.) 16, 549–560 (2004 ).

   Not in our library10.1016/j.clon.2004.06.007

9. 9.

   Personalized Medicine Coalition. The personalized medicine report. Opportunity, challenges, and the future (2017 ), http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/The_PM_Report.pdf

   Not in our library

10. 10.

    Maciejko L, Smalley M & Goldman A Cancer immunotherapy and personalized medicine: Emerging technologies and biomarker-based approaches. J. Mol. Biomark. Diagn 8, (2017 ).

    Not in our library10.4172/2155-9929.1000350

11. 11.

    Burney IA & Lakhtakia R Precision medicine: Where have we reached and where are we headed? Sultan Qaboos Univ. Med. J 17, e255–e258 (2017 ).

    Not in our library10.18295/squmj.2017.17.03.001

12. 12.

    Williams SC News feature: Capturing cancer’s complexity. Proc. Natl. Acad. Sci. U. S. A 112, 4509–4511 (2015 ).

    Not in our library10.1073/pnas.1500963112

13. 13.

    Soda M Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566 (2007 ).

    Not in our library10.1038/nature05945

14. 14.

    Ledermann J Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15, 852–861 (2014 ).

    Not in our library10.1016/s1470-2045(14)70228-1

15. 15.
    Personalized Medicine and Cancer · 2012

    No notice
16. 16.

    Agilent. Herceptest, https://www.agilent.com/en-us/products/pharmdx/herceptest-kits/herceptest

    Not in our library

17. 17.

    Myriad. Bracanalysis, https://myriad.com/products-services/hereditary-cancers/bracanalysis/

    Not in our library

18. 18.

    U.S. Food and Drug Administration. Mobile medical applications — Guidance for industry and food and drug administration staff (2015 ), https://www.fda.gov/downloads/MedicalDevices/…/UCM263366.pdf

    Not in our library

19. 19.

    U.S. Food and Drug Administration. FDA advances precision medicine initiative by issuing draft guidances on next generation sequencing-based tests (2016 ), https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm509814.htm

    Not in our library

20. 20.

    U.S. National Library of Medicine. What is the difference between precision medicine and personalized medicine? What about pharmacogenomics? (2018 ), https://ghr.nlm.nih.gov/primer/precisionmedicine/precisionvspersonalized

    Not in our library

21. 21.

    Appendix E. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease (The National Academies Press, 2011 ), pp. 124–145.

    Not in our library

22. 22.

    Chial H DNA sequencing technologies key to the human genome project. Nat. Educ 1, (2008 ).

    Not in our library

23. 23.

    Goodwin S, McPherson JD & McCombie WR Coming of age: Ten years of next-generation sequencing technologies. Nat. Rev. Genet 17, 333–351 (2016 ).

    Not in our library10.1038/nrg.2016.49

24. 24.

    Munroe DJ & Harris TJ Third-generation sequencing fireworks at marco island. Nat. Biotechnol 28, 426 (2010 ).

    Not in our library10.1038/nbt0510-426

25. 25.
    Transcriptomics technologies · 2017

    No notice
26. 26.

    Kukurba KR & Montgomery SB RNA sequencing and analysis. Cold Spring Harb. Protoc 2015, 951–969 (2015 ).

    Not in our library10.1101/pdb.top084970

27. 27.

    Buguliskis JS Could RNA-Seq become the workhorse of precision medicine? Plowing through transcriptional variations by harnessing the powerful next-gen technique. Genet. Eng. Biotechnol. News 35, 8–9 (2015 ).

    Not in our library

28. 28.

    Larance M & Lomond AI Multidimensional proteomics for cell biology. Nat. Rev. Mol. Cell. Biol 16, 269–280 (2015 ).

    Not in our library10.1038/nrm3970

29. 29.

    Han XM, Aslanian A & Yates JR Mass spectrometry for proteomics. Curr. Opin. Chem. Biol 12, 483–490 (2008 ).

    Not in our library10.1016/j.cbpa.2008.07.024

30. 30.

    Duarte TT & Spencer CT Personalized proteomics: The future of precision medicine. Proteomes 4, (2016 ).

    Not in our library10.3390/proteomes4040029

31. 31.

    Gregorich ZR & Ge Y Top-down proteomics in health and disease: Challenges and opportunities. Proteomics 14, 1195–1210 (2014 ).

    Not in our library10.1002/pmic.201300432

32. 32.

    Sidoli S Metabolic labeling in middle-down proteomics allows for investigation of the dynamics of the histone code. Epigenetics Chromatin 10, 34 (2017 ).

    Not in our library10.1186/s13072-017-0139-z

33. 33.

    Monteiro MS, Carvalho M, Bastos ML & Guedes de Pinho P Metabolomics analysis for biomarker discovery: Advances and challenges. Curr. Med. Chem 20, 257–271 (2013 ).

    Not in our library10.2174/092986713804806621

34. 34.

    Roessner U & Bowne J What is metabolomics all about? Biotechniques 46, 363 (2009 ).

    Not in our library10.2144/000113133

35. 35.

    Everett JR, Loo RL & Pullen FS Pharmacometabonomics and personalized medicine. Ann. Clin. Biochem 50, 523–545 (2013 ).

    Not in our library10.1177/0004563213497929

36. 36.

    Eckhart AD, Beebe K & Milburn M Metabolomics as a key integrator for “omic” advancement of personalized medicine and future therapies. Clin. Transl. Sci 5, 285–288 (2012 ).

    Not in our library10.1111/j.1752-8062.2011.00388.x

37. 37.

    Prosser GA, Larrouy-Maumus G & de Carvalho LPS Metabolomic strategies for the identification of new enzyme functions and metabolic pathways. EMBO Rep 15, 657–669 (2014 ).

    Not in our library10.15252/embr.201338283

38. 38.

    Li SZ, Todor A & Luo RY Blood transcriptomics and metabolomics for personalized medicine. Comput. Struct. Biotechnol. J 14, 1–7 (2016 ).

    Not in our library10.1016/j.csbj.2015.10.005

39. 39.

    Dunn WB & Ellis DI Metabolomics: Current analytical platforms and methodologies. Trac-Trend. Anal. Chem 24, 285–294 (2005 ).

    Not in our library

40. 40.

    Kaufmann A, Butcher P, Maden K, Walker S & Widmer M Comprehensive comparison of liquid chromatography selectivity as provided by two types of liquid chromatography detectors (high resolution mass spectrometry and tandem mass spectrometry): “Where is the crossover point?”. Anal. Chim. Acta 673, 60–72 (2010 ).

    Not in our library10.1016/j.aca.2010.05.020

Cited by papers we hold 6

• Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells · 2024
  No notice
• Molecular mechanisms of tumor resistance to radiotherapy · 2023
  No notice
• A scoping review of interactive and personalized web-based clinical tools to support treatment decision making in breast cancer · 2022
  Not checked
• Artificial Intelligence in Colorectal Cancer Screening, Diagnosis and Treatment. A New Era · 2021
  No notice
• Neoantigen: A New Breakthrough in Tumor Immunotherapy · 2021
  No notice
• The CCL20-CCR6 Axis in Cancer Progression · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.